Caduet's Japanese price may set precedent for combinations
This article was originally published in Scrip
Pfizer's combination cardiovascular product Caduet, Novartis's novel antihypertensive Rasilez and other products have been awarded prices in Japan and will be added to the reimbursement tariff on September 4th, clearing the way for launch.
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.